Form 8-K BIOCRYST PHARMACEUTICALS For: Feb 24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
Go back to Form 8-K BIOCRYST PHARMACEUTICALS For: Feb 24
February 24, 2025 1:18 PM EST
Piper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $23.00 price target on BioCryst Pharma (NASDAQ: BCRX)
The analyst comments "Remain OW rated on BCRX shares after a solid Q424 Orladeyo print, reporting $124.2M versus the $123.5M preliminary revenue pre-released last month.... More
February 24, 2025 8:58 AM EST
JPMorgan analyst Jessica Fye reiterated an Overweight rating and $10.00 price target on BioCryst Pharma (NASDAQ: BCRX)
The analyst comments "We think the ~3% upward guidance revision to FY25 Orladeyo revs by ~$18mm at the midpoint to $535-$550mm (vs prior guidance of $515-$535mm established earlier this year at our healthcare conference) will be well received as it supports 24% growth YoY for Orladeyo at the midpoint after 34% Orladeyo growth in 24. Well listen... More
